Exponent (NASDAQ:EXPO) Price Target Raised to $100.00

Exponent (NASDAQ:EXPO) had its target price boosted by equities researchers at JPMorgan Chase & Co. from $90.00 to $100.00 in a report issued on Friday, Benzinga reports. The firm currently has an “overweight” rating on the business services provider’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 24.60% from the stock’s current price.

A number of other research analysts have also recently commented on EXPO. UBS Group set a $72.00 price target on Exponent and gave the stock a “neutral” rating in a research report on Friday, July 31st. Weiss Ratings upgraded shares of Exponent from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, October 9th. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $86.00.

Exponent Stock Up 2.5%

EXPO traded up $1.95 on Friday, reaching $80.26. The company had a trading volume of 773,547 shares, compared to its average volume of 520,748. The stock has a market capitalization of $3.82 billion, a PE ratio of 35.99 and a beta of 0.69. Exponent has a 1 year low of $51.91 and a 1 year high of $83.18. The stock has a 50-day moving average price of $69.97 and a 200-day moving average price of $66.61.

Exponent (NASDAQ:EXPO) last issued its earnings results on Thursday, October 29th. The business services provider reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.04. Exponent had a net margin of 17.67% and a return on equity of 31.48%. The business had revenue of $173.73 million for the quarter, compared to analyst estimates of $149.64 million. During the same quarter in the prior year, the business posted $0.55 EPS. The company’s revenue for the quarter was up 11.7% on a year-over-year basis. As a group, analysts expect that Exponent will post 2.31 earnings per share for the current fiscal year.

Insider Buying and Selling at Exponent

In other Exponent news, CEO Catherine Corrigan sold 1,707 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $66.28, for a total transaction of $113,139.96. Following the completion of the transaction, the chief executive officer owned 129,108 shares in the company, valued at approximately $8,557,278.24. The trade was a 1.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.70% of the company’s stock.

Institutional Trading of Exponent

Institutional investors and hedge funds have recently modified their holdings of the stock. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Exponent in the 2nd quarter valued at about $26,000. Public Employees Retirement System of Ohio purchased a new position in Exponent during the 2nd quarter worth $29,000. Bessemer Group Inc. lifted its holdings in Exponent by 37.1% during the first quarter. Bessemer Group Inc. now owns 717 shares of the business services provider’s stock valued at $47,000 after purchasing an additional 194 shares during the last quarter. Allworth Financial LP purchased a new stake in shares of Exponent in the 2nd quarter valued at about $46,000. Finally, Farther Finance Advisors LLC increased its position in shares of Exponent by 36.4% in the third quarter. Farther Finance Advisors LLC now owns 959 shares of the business services provider’s stock valued at $63,000 after acquiring an additional 256 shares during the period. 92.37% of the stock is owned by institutional investors.

Exponent News Roundup

Here are the key news stories impacting Exponent this week:

• Positive Sentiment: Quarterly earnings and revenue topped estimates. Exponent reported third-quarter EPS of $0.64, above the $0.60 consensus estimate and up from $0.55 a year earlier. Revenue reached $173.7 million versus an expected $149.6 million, while year-over-year revenue increased 11.7%. Exponent Tops Q3 Earnings and Revenue Estimates
• Positive Sentiment: Profitability and cash generation remained solid. Reported net income was approximately $30.9 million, operating profit increased sharply, and operating cash flow was $30.9 million. The results indicate improving operating leverage as revenue expands. Exponent Releases Q3 2026 Earnings
• Positive Sentiment: Management raised its 2026 outlook. The improved guidance reinforces investor expectations for continued growth and supports the positive reaction to the earnings release. Exponent Posts Strong Q3 Results
• Positive Sentiment: The company declared a regular quarterly dividend of $0.31 per share. The dividend is payable December 18 to shareholders of record December 4, representing an annualized payout of $1.24 and a yield of roughly 1.5%. Exponent Declares Quarterly Dividend
• Neutral Sentiment: Exponent plans to acquire Crane Building Services & Utilities in a carve-out transaction. The deal could broaden its service offering, although financial terms and expected earnings benefits were not provided. Exponent to Acquire Crane Building Services and Utilities
• Negative Sentiment: Recent insider trading has been weighted toward selling, with 10 reported sales and only one purchase over the past six months. This may create a modest sentiment headwind, though it is less significant than the earnings beat.

About Exponent

Exponent, Inc is a science and engineering consulting company that helps clients investigate complex technical issues, manage risks, and develop solutions. Its consultants work across disciplines including engineering, materials science, biomechanics, human factors, environmental science, health, data sciences, and economics.

The company provides failure analysis, product safety and testing, accident reconstruction, environmental and health assessments, regulatory support, and expert testimony.